Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive dementia and loss of cognitive abilities. Until now, AD remains incurable. The principal biological target for AD therapy is acetylcholinesterase (AChE). Thus, the search for new drug candidates like AChE inhibitors constitutes an essential part for the discovery of more potent anti-AD agents. In general terms, rational drug design methodologies have played a decisive role. The present work is focused on the current state of the Ligand-Based Drug Design (LBDD) methods which have been applied to the elucidation of new molecular entities with high anti-AChE activity. Also, as a contribution to this field, we suggest a promising fragment-based approach for the search and prediction of new AChE inhibitors and for the fast and efficient extraction of substructural alerts which are responsible for the anti-AChE activity.
Keywords: AChE inhibitors, QSAR, 3D-QSAR, linear discriminant analysis, fragments, AChE, anti-AD agents, Ligand-Based Virtual Screening (LB-VS), parsimony, ArOCON, LBDD
Mini-Reviews in Medicinal Chemistry
Title:Discovery of Anti-Alzheimer Agents: Current Ligand-Based Approaches toward the Design of Acetylcholinesterase Inhibitors
Volume: 12 Issue: 6
Author(s): A. Speck-Planche, F. Luan and M. N.D.S. Cordeiro
Affiliation:
Keywords: AChE inhibitors, QSAR, 3D-QSAR, linear discriminant analysis, fragments, AChE, anti-AD agents, Ligand-Based Virtual Screening (LB-VS), parsimony, ArOCON, LBDD
Abstract: Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive dementia and loss of cognitive abilities. Until now, AD remains incurable. The principal biological target for AD therapy is acetylcholinesterase (AChE). Thus, the search for new drug candidates like AChE inhibitors constitutes an essential part for the discovery of more potent anti-AD agents. In general terms, rational drug design methodologies have played a decisive role. The present work is focused on the current state of the Ligand-Based Drug Design (LBDD) methods which have been applied to the elucidation of new molecular entities with high anti-AChE activity. Also, as a contribution to this field, we suggest a promising fragment-based approach for the search and prediction of new AChE inhibitors and for the fast and efficient extraction of substructural alerts which are responsible for the anti-AChE activity.
Export Options
About this article
Cite this article as:
Speck-Planche A., Luan F. and N.D.S. Cordeiro M., Discovery of Anti-Alzheimer Agents: Current Ligand-Based Approaches toward the Design of Acetylcholinesterase Inhibitors, Mini-Reviews in Medicinal Chemistry 2012; 12 (6) . https://dx.doi.org/10.2174/138955712800493744
DOI https://dx.doi.org/10.2174/138955712800493744 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Design and Development of Resveratrol NLCs and their Role in Synaptic Transmission of Acetylcholine in C. elegans Model
Current Drug Therapy Application of Resveratrol in Diabetes: Rationale, Strategies and Challenges
Current Molecular Medicine Progressions of Sleep, Memory and Depression Applicable to Psychoanalysis: A Review
Current Psychiatry Reviews Reconstructing the Hsp90/Tau Machine
Current Enzyme Inhibition Treatment of Cardiovascular Risk Factors in Women
Current Medicinal Chemistry Brain Aging in African-Americans: The Atherosclerosis Risk in Communities (ARIC) Experience
Current Alzheimer Research Editorial
Current Medical Imaging Histone Deacetylase Inhibitors: A Novel Therapeutic Approach to Huntingtons Disease (Complex Mechanism of Neuronal Death).
Current Alzheimer Research Resveratrol Rescues Tau-Induced Cognitive Deficits and Neuropathology in a Mouse Model of Tauopathy
Current Alzheimer Research Nuclear Imaging of Post-infarction Inflammation in Ischemic Cardiac Diseases - New Radiotracers for Potential Clinical Applications
Current Radiopharmaceuticals Type 2 Diabetes Mellitus and Invokana: An FDA Approved Drug
Current Diabetes Reviews Editorial (Thematic Issue: The Crosstalk between Non-Pharmaceutical and Pharmaceutical Approaches to Prevention and Treatment of Chronic Diseases: Current Concepts and Perspectives)
Current Pharmaceutical Design Viral Reservoirs an Impediment to HAART: New Strategies to Eliminate HIV-1
Current Drug Targets - Infectious Disorders ACAT1 as a Therapeutic Target and its Genetic Relationship with Alzheimer's Disease
Current Alzheimer Research Meet Our Editorial Board Member:
Reviews on Recent Clinical Trials Sulfur – Containing Amino Acids in Seizures: Current State of the Art
Current Medicinal Chemistry Hippocampal BDNF Expression in a Tau Transgenic Mouse Model
Current Alzheimer Research Older Adults Prescribed Methadone: A Review of the Literature Across the Life Span from Opiate Initiation to Methadone Maintenance Treatment
Current Drug Abuse Reviews Editorial (Thematic Issue: “Infectious Diseases in Asia-Pacific: Historical and Contemporary Perspectives”)
Infectious Disorders - Drug Targets Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued)